Compare NBIX & FNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | FNF |
|---|---|---|
| Founded | 1992 | 1847 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 14.0B |
| IPO Year | 1996 | 2005 |
| Metric | NBIX | FNF |
|---|---|---|
| Price | $132.09 | $50.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 2 |
| Target Price | ★ $180.82 | $60.50 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.13% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | 2.21 |
| Revenue | $161,626,000.00 | ★ $14,445,000,000.00 |
| Revenue This Year | $24.73 | $10.90 |
| Revenue Next Year | $13.14 | $5.44 |
| P/E Ratio | $28.24 | ★ $22.79 |
| Revenue Growth | ★ 977.51 | 5.58 |
| 52 Week Low | $101.15 | $42.78 |
| 52 Week High | $160.18 | $65.33 |
| Indicator | NBIX | FNF |
|---|---|---|
| Relative Strength Index (RSI) | 49.41 | 65.18 |
| Support Level | $124.29 | $50.82 |
| Resistance Level | $136.23 | $60.63 |
| Average True Range (ATR) | 4.30 | 1.09 |
| MACD | 0.12 | 0.69 |
| Stochastic Oscillator | 57.28 | 96.02 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Fidelity National Financial Inc is a provider of (i) title insurance, escrow and other title-related services, including trust activities, trustee sales guarantees, recordings and reconveyances and home warranty and (ii) transaction services to the real estate and mortgage industries. It operates in three segments: Title, F&G, Corporate and Other. The title segment that derives the majority of revenue consists of the operations of title insurance underwriters and related businesses, which provide title insurance and escrow and other title-related services including trust activities, trustee sales guarantees, and home warranty products. All of the company's revenue is generated in the United States.